Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VIR-2218 + peginterferon alfa-2a
- Development stage
- Unknown
- Lead developer
- Vir Biotechnology
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
VIR-2218 + peginterferon alfa-2a is an investigational combination therapy for chronic hepatitis B virus (HBV) infection. VIR-2218 is a small interfering RNA (siRNA) designed to inhibit the production of all HBV proteins (X, polymerase, S and core), which may be acting as immune tolerogens. Peginterferon alfa-2a is a modified form of recombinant human interferon that stimulates the body's innate antiviral response by binding to human type 1 interferon receptors and activating the JAK/STAT pathway. This combination approach is being evaluated for its potential to achieve a functional cure for chronic HBV infection.
- Brand names
- Pegasys
- Other names
- elebsiran + pegylated interferon alfaBRII-835 + PEG-IFNαBRII-835 + PEG-interferon-alpha
02
Targets
HBV RNA (Hepatitis B virus RNA)IFNAR1 (Interferon alpha/beta receptor 1)IFNAR2 (Interferon alpha/beta receptor subunit 2)
Beyond the preview
Go deeper on VIR-2218 + peginterferon alfa-2a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VIR-2218 + peginterferon alfa-2a.